What is B. Riley’s Estimate for MDGL Q4 Earnings?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Research analysts at B. Riley issued their Q4 2026 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a research report issued on Tuesday, November 4th. B. Riley analyst W. Wood forecasts that the biopharmaceutical company will earn $5.18 per share for the quarter. B. Riley currently has a “Buy” rating and a $560.00 price objective on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%.The firm had revenue of $287.27 million during the quarter, compared to analysts’ expectations of $244.33 million.

Several other analysts have also weighed in on the company. Truist Financial initiated coverage on Madrigal Pharmaceuticals in a report on Tuesday, October 14th. They issued a “buy” rating and a $580.00 price objective for the company. Citigroup reiterated an “outperform” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday. Bank of America raised Madrigal Pharmaceuticals from an “underperform” rating to a “neutral” rating and upped their price target for the company from $266.00 to $445.00 in a research report on Monday. Piper Sandler lifted their price objective on shares of Madrigal Pharmaceuticals from $400.00 to $540.00 and gave the stock an “overweight” rating in a report on Wednesday, October 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, October 8th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $528.42.

Madrigal Pharmaceuticals Stock Up 7.0%

Shares of Madrigal Pharmaceuticals stock opened at $475.87 on Thursday. The business has a 50-day moving average of $435.09 and a 200-day moving average of $355.41. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.11 and a quick ratio of 4.78. The company has a market capitalization of $10.57 billion, a PE ratio of -37.03 and a beta of -1.04. Madrigal Pharmaceuticals has a 1-year low of $265.00 and a 1-year high of $496.98.

Insider Activity at Madrigal Pharmaceuticals

In other news, General Counsel Shannon T. Kelley sold 1,304 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $367.81, for a total transaction of $479,624.24. Following the sale, the general counsel owned 9,173 shares of the company’s stock, valued at approximately $3,373,921.13. The trade was a 12.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kenneth Bate sold 10,000 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $365.20, for a total value of $3,652,000.00. Following the sale, the director directly owned 2,627 shares in the company, valued at approximately $959,380.40. This trade represents a 79.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have purchased 165,683 shares of company stock valued at $61,921,142 and have sold 248,642 shares valued at $91,388,103. 21.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Paulson & CO. Inc. raised its holdings in Madrigal Pharmaceuticals by 2.8% during the first quarter. Paulson & CO. Inc. now owns 2,099,523 shares of the biopharmaceutical company’s stock worth $695,425,000 after purchasing an additional 57,523 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Madrigal Pharmaceuticals by 96.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 376,163 shares of the biopharmaceutical company’s stock worth $113,842,000 after purchasing an additional 184,554 shares in the last quarter. Woodline Partners LP raised its holdings in Madrigal Pharmaceuticals by 2.7% during the first quarter. Woodline Partners LP now owns 317,433 shares of the biopharmaceutical company’s stock worth $105,143,000 after purchasing an additional 8,316 shares in the last quarter. Bank of America Corp DE raised its holdings in Madrigal Pharmaceuticals by 12.7% during the second quarter. Bank of America Corp DE now owns 277,221 shares of the biopharmaceutical company’s stock worth $83,898,000 after purchasing an additional 31,260 shares in the last quarter. Finally, Hood River Capital Management LLC raised its holdings in Madrigal Pharmaceuticals by 0.3% during the second quarter. Hood River Capital Management LLC now owns 244,738 shares of the biopharmaceutical company’s stock worth $74,068,000 after purchasing an additional 744 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.